A calf thymus acid lysate improves clinical symptoms and T-cell defects in the early stages of HIV infection: second report. NLM AIDSLINE Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


A calf thymus acid lysate improves clinical symptoms and T-cell defects in the early stages of HIV infection: second report.

Eur J Cancer Clin Oncol. 1987 Dec;23(12):1915-9. Unique Identifier : AIDSLINE MED/88137360
Valesini G; Barnaba V; Benvenuto R; Balsano F; Mazzanti P; Cazzola P; Instituto Clinica Medica I, University of Rome La Sapienza,; Milan, Italy.

Abstract: Thymomodulin is a calf thymus acid lysate capable of inducing T lymphocyte maturation. Fifteen patients with HIV infection at different stages according to the Walter Reed classification were treated with 60 mg/day of thymomodulin syrup for more than 50 days. Two WR6B subjects had clinical and immunological parameters unchanged and died, while the patient suffering from Kaposi's sarcoma presented an evident clinical and laboratory improvement with remission of the neoplasia. The other 12 patients ranging from WR2 to WR5B showed an improvement of clinical symptoms after thymomodulin therapy accompanied by the normalization of CD4/CD8 ratio (P less than 0.001). This helpers/suppressors increase was due to a significant increase of CD4 cells (P less than 0.01) and also to a decrease of the CD8 lymphocytes (P less than 0.05). Thymomodulin administration did not cause an enhancement of the urinary levels of neopterin, a marker of T-cell activation.
Keywords: Acquired Immunodeficiency Syndrome/BLOOD/*DRUG THERAPY Adult Biopterin/ANALOGS & DERIVATIVES/BLOOD Female Human Male Sarcoma, Kaposi's/DRUG THERAPY T-Lymphocytes/*DRUG EFFECTS Thymus Extracts/*THERAPEUTIC USE JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/blood/KWDdrugtherapyadultbiopterin/analogs&derivatives/bloodfemalehumanmalesarcoma,kaposi's/drugtherapyt-lymphocytes/KWDdrugeffectsthymusextracts/KWDtherapeuticusejournalarticle
880630
M8860433

Copyright © 1988 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .